Diasorin SpAWBO:DIAS +2.47%74 EBIT per Share is €4.06 as of Dec. 2025. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.06 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 75% on this metric.
Diasorin SpA's EBIT per Share for the
three
months ended in Dec. 2025 was €0.55.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €4.06.
During the past 12 months, the average EBIT per Share Growth Rate of Diasorin SpA was 0.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -9.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -8.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 6.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Diasorin SpA's EBIT per Share or its related term are showing as below:
WBO:DIAS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14.8 Med: 12.4 Max: 96.7
Current: -9.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Diasorin SpA was 96.70% per year. The lowest was -14.80% per year. And the median was 12.40% per year.
WBO:DIAS's 3-Year EBIT Growth Rate is ranked worse than 75% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs WBO:DIAS: -9.50
Diasorin SpA's EBIT for the
three
months ended in Dec. 2025 was €31 Mil.
Diasorin SpA (WBO:DIAS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Diasorin SpA EBIT per Share Related Terms
Diasorin SpA EBIT per Share Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (WBO:DIAS) has a EBIT per Share of €4.06 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Diasorin SpA and its competitors. According to the industry distribution chart, Diasorin SpA ranks #126 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 75%.
Is Diasorin SpA's EBIT per Share too high?
Diasorin SpA's current EBIT per Share is €4.06. Based on the distribution chart, Diasorin SpA ranks #126 out of 168 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #126 out of 168 companies for EBIT per Share. This places Diasorin SpA in the lower half of its industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current EBIT per Share is €4.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.06, compared to a current price of €69.68 — trading 22.6% below its estimated fair value. The current EBIT per Share is €4.06. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current EBIT per Share is €4.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.68 is trading 22.6% below its estimated GF Value™ of €90.06.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for WBO:DIAS:
EBIT per Share: €4.06
GF Value™: €90.06 vs. price of €69.68 (22.6% below fair value)
No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for WBO:DIAS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DIAS has been successfully added to your 
